Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4391022 PF-07220060 plus fulvestrant vs investigator’s choice in HR+/HER2- advanced breast cancer after CDK4/6i
2023-506487-13-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival (PFS) by BICR. Started Jul 2024; status: completed.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506487-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506487-13-00.